As a breast surgeon, I guide patients through the emotional tidal wave of a cancer diagnosis, offering clarity and support in navigating treatment decisions. In our close-knit team, we are committed to delivering compassionate and empathetic care, providing comprehensive support beyond treatment and with a caring touch.
Work and Credentials:
Primary Location
Position
Breast Surgeon
Board Certification
American Board of Surgery
Fellowship
Johns Hopkins Hospital
Internship
Walter Reed Army Medical Center
Residency
Walter Reed Army Medical Center
Medical School
Duke University School of Medicine
College
United States Military Academy
Special Interests
Breast Surgery
Matthew T. Hueman, MD, FACS, FSSO, is a board-certified breast surgical oncologist, dedicated to providing comprehensive and personalized cancer care for his patients.
Dr. Hueman completed his undergraduate degree at the United States Military Academy at West Point, New York before earning his medical degree from Duke University School of Medicine in Durham, North Carolina. He then completed his general surgery residency at Walter Reed Army Medical Center in Washington, DC before finishing his surgical oncology fellowship at Johns Hopkins Hospital in Maryland. He is certified from the American Board of Surgery and the Society of Surgical Oncology.
During his distinguished military career, where he served as Chief Medical Officer and a trauma surgeon during six combat deployments, Dr. Hueman also held multiple leadership roles in cancer care and education at Walter Reed National Military Medical Center.
Dr. Hueman was named Washingtonian Top Doctor, chosen by his peers. He is an active member of several professional organizations where he is a fellow of the American College of Surgeons, a fellow of the Society of Surgical Oncology, and a member of the American Society of Breast Surgeons.
In his spare time, Dr. Hueman enjoys spending time with his wife and three children. He is an avid long-distance runner and enjoys outdoor activities like camping, kayaking, walking in parks, and basketball. He also enjoys supporting his children at their local baseball and soccer practices and games.
LEAVE A GOOGLE REVIEW FOR DR. HUEMAN
Physician Publications
May 3, 2022
Circulating Cell-free DNA in Serum as a Marker for the Early Detection of Tumor Recurrence in Breast Cancer Patients
Read MoreJanuary 7, 2020
Proteomic Analysis of Inflammatory Biomarkers Associated With Breast Cancer Recurrence
Read MoreDecember 26, 2019
ASO Author Reflections: Mitigating Survival Disparities in African American Women with Breast Cancer within the US Military Healthcare System-The Impact of Equivalent Care
Read MoreMore Publications by Matthew T. Hueman, MD, FACS, FSSO
November 26, 2019
Evaluation of Surgical Disparities Between African American and European American Women Treated for Breast Cancer Within an Equal-Access Military Hospital
Read MoreMarch 1, 2019
Serum Biomarkers for Racial Disparities in Breast Cancer Progression
Read MoreNovember 1, 2018
Comparative Survival Analysis of Invasive Breast Cancer Patients Treated by a U.S. Military Medical Center and Matched Patients From the U.S. General Population
Read MoreJuly 1, 2016
An Algorithm for Creating Prognostic Systems for Cancer
Read MoreFebruary 24, 2016
An algorithm for expanding the TNM staging system
Read MoreJuly 1, 2015
Tumour location within the breast: Does tumour site have prognostic ability?
Read MoreOctober 1, 2008
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Read MoreFebruary 1, 2008
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Read MoreFebruary 1, 2007
Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine
Read MoreJuly 1, 2006
Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine
Read MoreOctober 1, 2005
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients
Read More
